Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 25, 2026, 12:21 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 73 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: voriconazole (Vfend) Clear all
Terminated No phase listed Observational

An Assessment of Voriconazole Pharmacokinetics and Pharmacogenetics in Liver Transplant Recipients - Pilot Study

NCT00371605
View directory record Official record
Conditions
Liver Transplant, Fungal Infection
Interventions
Not listed
Lead sponsor
University of Pittsburgh
Other
Eligibility
18 Years and older
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2007
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Dec 16, 2007 · Synced Sep 25, 2026, 12:21 AM EDT
Completed No phase listed Observational

Intravenous Voriconazole in Patients With Renal Compromise

NCT00332410
View directory record Official record
Conditions
Renal Transplant
Interventions
Not listed
Lead sponsor
University of Pittsburgh
Other
Eligibility
18 Years and older
Enrollment
150 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2015
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jun 11, 2018 · Synced Sep 25, 2026, 12:21 AM EDT
Recruiting Phase 2 Interventional

Phase 2 EL219 Versus Liposomal Amphotericin B or Voriconazole for Early Antifungal Therapy

NCT07215273
View directory record Official record
Conditions
Invasive Mould Infection
Interventions
EL219, Active Comparator- IV Antifungal (LAmB or voriconazole)
Drug
Lead sponsor
Elion Therapeutics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026
U.S. locations
9
States / cities
Birmingham, Alabama • Sacramento, California • Augusta, Georgia + 6 more
Source: ClinicalTrials.gov public record
Updated Sep 15, 2026 · Synced Sep 25, 2026, 12:21 AM EDT
Completed Phase 2 Interventional Results available

Liposomal Amphotericin B (Ambisome) Versus Oral Voriconazole for the Prevention of Invasive Fungal Infections

NCT00418951
View directory record Official record
Conditions
Acute Myelogenous Leukemia, Myelodysplastic Syndrome
Interventions
Voriconazole, Liposomal amphotericin B
Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2009
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Aug 6, 2012 · Synced Sep 25, 2026, 12:21 AM EDT
Completed Phase 3 Interventional

An Open Label, Non-Comparative, Multicenter, Phase III Trial of the Efficacy, Safety and Toleration of Voriconazole in the Primary or Secondary Treatment of Invasive Fungal Infections

NCT00001810
View directory record Official record
Conditions
Aspergillosis, Candidiasis, Fungemia, Mycoses
Interventions
Voriconazole
Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
Not listed
Enrollment
300 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1999 – 2000
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 3, 2008 · Synced Sep 25, 2026, 12:21 AM EDT
Completed Phase 3 Interventional Results available

Mycotic Ulcer Treatment Trial I

NCT00996736
View directory record Official record
Conditions
Corneal Ulcer, Eye Infections, Fungal
Interventions
Natamycin, Voriconazole
Drug
Lead sponsor
University of California, San Francisco
Other
Eligibility
16 Years and older
Enrollment
323 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Jul 31, 2018 · Synced Sep 25, 2026, 12:21 AM EDT
Completed Not applicable Interventional

Voriconazole Compared With Itraconazole in Preventing Fungal Infections in Patients Undergoing Allogeneic Hematopoietic Stem Cell Transplantation

NCT00079222
View directory record Official record
Conditions
Cancer
Interventions
itraconazole, voriconazole
Drug
Lead sponsor
Jonsson Comprehensive Cancer Center
Other
Eligibility
12 Years to 120 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2003
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Aug 2, 2020 · Synced Sep 25, 2026, 12:21 AM EDT
Completed No phase listed Observational

Voriconazole Prophylaxis Against Aspergillosis in Lung Transplant Recipients

NCT00177827
View directory record Official record
Conditions
Post Lung Transplantation
Interventions
Not listed
Lead sponsor
University of Pittsburgh
Other
Eligibility
18 Years and older
Enrollment
104 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2006
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Dec 2, 2009 · Synced Sep 25, 2026, 12:21 AM EDT
Terminated Phase 2 Interventional Results available

Voriconazole and Caspofungin Acetate in Treating Invasive Fungal Infections in Patients With Weakened Immune Systems

NCT00238355
View directory record Official record
Conditions
Infection, Unspecified Adult Solid Tumor, Protocol Specific
Interventions
caspofungin acetate, voriconazole
Drug
Lead sponsor
OHSU Knight Cancer Institute
Other
Eligibility
18 Years to 120 Years
Enrollment
13 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2008
U.S. locations
1
States / cities
Portland, Oregon
Source: ClinicalTrials.gov public record
Updated Apr 26, 2025 · Synced Sep 25, 2026, 12:21 AM EDT
Recruiting Phase 2 Interventional

A Platform Protocol to Investigate Post-Transplant Cyclophosphamide-Based Graft-Versus-Host Disease Prophylaxis in Patients With Hematologic Malignancies Undergoing Mismatched Unrelated Donor Peripheral Blood Stem Cell Transplantation

NCT06859424
View directory record Official record
Conditions
AML (Acute Myelogenous Leukemia), Acute Lymphoid Leukemia (ALL), Acute Leukemia (Category), MDS (Myelodysplastic Syndrome), CML (Chronic Myelogenous Leukemia), CLL (Chronic Lymphocytic Leukemia), Prolymphocyctic Leukemia, Chronic Myelomonocytic Leukemia (CMML), Myeloproliferative Neoplasm (MPN), Lymphoma, Myelofibrosis
Interventions
Conditioning Regimen A, Conditioning Regimen B, Conditioning Regimen C, Conditioning Regimen D, Conditioning Regimen E, Hematopoietic Cell Transplantation, PTCy (50 mg/kg D3, D4), PTCy (25 mg/kg D3, D4), Post-transplant Tacrolimus, Post-transplant Mycophenolate mofetil, Post-transplant Abatacept, Post-transplant Ruxolitinib, Supportive Care: Growth Factors, Supportive Care: Blood Products, Supportive Care: Infection Prophylaxis, Supportive Care: Intravenous immune globulin (IVIG), Supportive Care: Seizure prophylaxis, Supportive Care: Monitoring and management of CRS, Supportive Care: Prophylaxis against infections, Supportive Care: Prophylaxis against infections, Supportive Care: Lipid elevations, Study treatment compliance, Prohibited Concomitant Therapy, Permitted Concomitant Therapy
Drug · Procedure · Other
Lead sponsor
Center for International Blood and Marrow Transplant Research
Network
Eligibility
18 Years to 66 Years
Enrollment
358 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
13
States / cities
Birmingham, Alabama • Duarte, California • Palo Alto, California + 10 more
Source: ClinicalTrials.gov public record
Updated Mar 16, 2026 · Synced Sep 25, 2026, 12:21 AM EDT
Withdrawn Phase 2 Interventional

Pilot Study to Compare Topical Voriconazole to Placebo as a Pain Reducing Agent

NCT02689713
View directory record Official record
Conditions
Pain, Thermal Injury, Burns, Hyperalgesia
Interventions
Voriconazole (topical), Topical Sterile Water Placebo Group
Drug
Lead sponsor
Kenneth Hargreaves
Other
Eligibility
18 Years to 60 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018
U.S. locations
1
States / cities
San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Dec 16, 2018 · Synced Sep 25, 2026, 12:21 AM EDT
Completed Phase 3 Interventional Results available

Beta Glucan Assay in Patients Receiving Voriconazole Prophylaxis

NCT00904995
View directory record Official record
Conditions
Leukemia, Fungal Infection
Interventions
Voriconazole
Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
23 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Aug 6, 2012 · Synced Sep 25, 2026, 12:21 AM EDT
Terminated Phase 1 Interventional Results available

Study of AZD0466 Monotherapy or in Combination in Patients With Advanced Haematological Malignancies

NCT04865419
View directory record Official record
Conditions
Haematological Malignancies
Interventions
AZD0466, Voriconazole
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 130 Years
Enrollment
46 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
5
States / cities
Duarte, California • Jacksonville, Florida • Chicago, Illinois + 2 more
Source: ClinicalTrials.gov public record
Updated Jun 14, 2025 · Synced Sep 25, 2026, 12:21 AM EDT
Completed Phase 3 Interventional

An Open Label, Non-Comparative, Multicenter, Phase III Trial of the Efficacy, Safety and Toleration of Voriconazole in the Primary or Secondary Treatment of Invasive Fungal Infections

NCT00001757
View directory record Official record
Conditions
Mycoses
Interventions
Voriconazole
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
Not listed
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1997 – 2000
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 3, 2008 · Synced Sep 25, 2026, 12:21 AM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

To Determine The Amount Of Voriconazole In The Brain After 2 Loading Doses And 3 Maintenance Doses Over 3 Days

NCT00300677
View directory record Official record
Conditions
Infections, Fungal
Interventions
voriconazole
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 55 Years · Male only
Enrollment
12 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007 – 2008
U.S. locations
1
States / cities
Belmont, Massachusetts
Source: ClinicalTrials.gov public record
Updated Oct 13, 2009 · Synced Sep 25, 2026, 12:21 AM EDT
Completed Not applicable Interventional

A Prospective Trial to Assess Cost and Clinical Outcomes of a Clinical Pharmacogenomic Program

NCT02297126
View directory record Official record
Conditions
Adverse Drug Reaction
Interventions
Pharmacogenetic Intervention Arm (pharmacogenetic testing)
Other
Lead sponsor
Indiana University
Other
Eligibility
18 Years and older
Enrollment
4,465 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2019
U.S. locations
1
States / cities
Indianapolis, Indiana
Source: ClinicalTrials.gov public record
Updated Jan 7, 2021 · Synced Sep 25, 2026, 12:21 AM EDT
Completed No phase listed Observational

Voriconazole Blood Levels and Toxicity

NCT00359541
View directory record Official record
Conditions
Pharmacology
Interventions
Not listed
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
12 Years and older
Enrollment
98 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2010
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Jul 1, 2017 · Synced Sep 25, 2026, 12:21 AM EDT
Completed Phase 3 Interventional Results available

Isavuconazole (BAL8557) in the Treatment of Candidemia and Other Invasive Candida Infections

NCT00413218
View directory record Official record
Conditions
Candidiasis, Invasive, Candidemia, Mycoses
Interventions
Isavuconazole, Caspofungin, Voriconazole
Drug
Lead sponsor
Astellas Pharma Inc
Industry
Eligibility
18 Years and older
Enrollment
450 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2015
U.S. locations
18
States / cities
Birmingham, Alabama • Palm Desert, California • Sacramento, California + 15 more
Source: ClinicalTrials.gov public record
Updated Dec 9, 2024 · Synced Sep 25, 2026, 12:21 AM EDT
Completed No phase listed Observational

PEACE: Pediatric Antifungal Comparative Effectiveness

NCT01869829
View directory record Official record
Conditions
Pediatric Invasive Candidiasis
Interventions
Observational antifungal therapy
Drug
Lead sponsor
Duke University
Other
Eligibility
120 Days to 18 Years
Enrollment
750 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2018
U.S. locations
27
States / cities
Little Rock, Arkansas • Orange, California • Palo Alto, California + 24 more
Source: ClinicalTrials.gov public record
Updated Jan 27, 2022 · Synced Sep 25, 2026, 12:21 AM EDT
Completed Phase 1 Interventional

Voriconazole to Prevent Systemic Fungal Infections in Children

NCT00005912
View directory record Official record
Conditions
Aspergillosis, Candidiasis, Fungal Diseases, Mycoses
Interventions
Voriconazole
Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
Not listed
Enrollment
48 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2000 – 2001
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 3, 2008 · Synced Sep 25, 2026, 12:21 AM EDT
Completed Phase 3 Interventional

Comparison of Voriconazole and Amphotericin B in Treating Patients With Aspergillosis

NCT00003031
View directory record Official record
Conditions
Infection, Pulmonary Complications
Interventions
amphotericin B deoxycholate, voriconazole
Drug
Lead sponsor
European Organisation for Research and Treatment of Cancer - EORTC
Network
Eligibility
12 Years and older
Enrollment
212 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 1997
U.S. locations
1
States / cities
Wethersfield, Connecticut
Source: ClinicalTrials.gov public record
Updated Jul 1, 2012 · Synced Sep 25, 2026, 12:21 AM EDT
Recruiting Phase 1Phase 2 Interventional

Decitabine and Venetoclax Treatment as Maintenance Therapy in Patients Post Allograft Stem Cell Transplant

NCT06129734
View directory record Official record
Conditions
Myeloid Malignancy, Acute Myeloid Leukemia
Interventions
Venetoclax, Decitabine
Drug
Lead sponsor
Benjamin Tomlinson
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
2
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Apr 26, 2026 · Synced Sep 25, 2026, 12:21 AM EDT
Completed No phase listed Observational

Registry of Patients Treated With Systemic Mold-Active Triazoles

NCT03066011
View directory record Official record
Conditions
Invasive Fungal Infection
Interventions
Isavuconazonium sulfate, Voriconazole, Posaconazole
Drug
Lead sponsor
Astellas Pharma Global Development, Inc.
Industry
Eligibility
Not listed
Enrollment
2,015 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2020
U.S. locations
56
States / cities
Birmingham, Alabama • Phoenix, Arizona • Tucson, Arizona + 42 more
Source: ClinicalTrials.gov public record
Updated Oct 20, 2024 · Synced Sep 25, 2026, 12:21 AM EDT
Completed Phase 4 Interventional Results available

A Trial Comparing Efficacy and Safety of Voriconazole Administered With Therapeutic Drug Monitoring vs. Standard Dosing

NCT01416025
View directory record Official record
Conditions
Fungal Infection
Interventions
Prospective TDM Arm
Drug
Lead sponsor
Johns Hopkins University
Other
Eligibility
12 Years to 100 Years
Enrollment
29 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Aug 17, 2016 · Synced Sep 25, 2026, 12:21 AM EDT